Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + toripalimab versus FOLFIRI as second-line treatment for advanced neuroendocrine carcinoma
CTR20211631Phase 3Active
- Sponsor
- HUTCHMED
- Start
- Sep 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of surufatinib, toripalimab, irinotecan, fluorouracil and folinic acid in neuroendocrine carcinoma (NEC) (2 arms), sponsored by HUTCHMED. Primary endpoint: Overall survival. Started Sep 2021; status: active.
02
Drugs
surufatinibtoripalimabirinotecanfluorouracilfolinic acid
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20211631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211631.